Latest Recruitment News

Amplia Therapeutics reported encouraging mature data from its ACCENT trial, initiated a Phase 2b pancreatic cancer study, launched an ovarian cancer trial, and refreshed its board leadership while maintaining a solid cash balance of A$24 million.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Cavalier Resources has lifted the net present value of its Crawford Gold Project by 50%, securing a $23 million financing package and advancing pre-production activities as it moves closer to development.

Hiremii Limited ended FY26 with its strongest quarter yet, reporting positive adjusted EBITDA, record gross profit, and a strategic rebrand to AQYR focused on AI-powered workforce intelligence.

Geopacific Resources has completed a Definitive Feasibility Study for its Woodlark Gold Project, revealing robust economics and a clear path to development with a targeted Final Investment Decision by early 2027.

Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.

Clinuvel Pharmaceuticals targets year-end for topline results from its pivotal vitiligo trial of SCENESSE® combined with narrowband UVB, aiming to expand the drug's use beyond its current rare disease indication.

EQ Resources delivered a breakout quarter with A$79 million revenue and A$22.5 million operating cash flow, driven by a 176% production surge at Mt Carbine and soaring tungsten prices. The company greenlit a major expansion to double crushing capacity, targeting commissioning in Q3 FY2027.

Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.

Syntara secured positive FDA feedback for its Phase 2b amsulostat trial in myelofibrosis and raised $8 million to extend its cash runway to Q3 2027, while preliminary data showed promising brain inflammation reduction in a Parkinson’s-related disorder.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.